Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 100 of 253 publications.

Earnshaw SR, Mullins D, Brogan A, Hogue S. Building a budget impact model: budget impact analysis training. Presented at the 2017 ISPOR Training Courses; September 2017. New Brunswick, NJ.

Wolowacz S, Mauskopf J, Earnshaw SR. Determining the analytic framework. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.11-34. doi: 10.1007/978-3-319-50482-7

Wolowacz S, Mauskopf J, Earnshaw SR. Estimating condition-related costs. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.91-101. doi: 10.1007/978-3-319-50482-7

Brogan A, Earnshaw SR, Mauskopf J. The computing framework and calculations. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.103-28. doi: 10.1007/978-3-319-50482-7

Brogan A, Earnshaw SR, Mauskopf J. Software and computer interface. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.151-64. doi: 10.1007/978-3-319-50482-7

Earnshaw SR, Mauskopf J. Estimating the diagnosed, treated, and eligible population. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.35-57. doi: 10.1007/978-3-319-50482-7

Earnshaw SR, Mauskopf J. Additional pragmatic topics. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.189-201. doi: 10.1007/978-3-319-50482-7

Mauskopf J, Earnshaw SR. Introduction to budget-impact analysis. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.1-10. doi: 10.1007/978-3-319-50482-7

Mauskopf J, Earnshaw SR. Uncertainty analysis. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.129-38. doi: 10.1007/978-3-319-50482-7

Mauskopf J, Earnshaw SR. Validation. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.139-50. doi: 10.1007/978-3-319-50482-7

Mauskopf J, Earnshaw SR. Reporting budget-impact analyses. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.165-88. doi: 10.1007/978-3-319-50482-7

Mauskopf J, Wolowacz S, Earnshaw SR. Alternative interventions. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.203-16. doi: 10.1007/978-3-319-50482-7

Mauskopf J, Earnshaw SR, Brogan A. Creating your own budget-impact analyses today and tomorrow. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.217-24. doi: 10.1007/978-3-319-50482-7

Brodtkorb TH, Mauskopf J, Earnshaw SR. Estimating the treatment mix. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.59-69. doi: 10.1007/978-3-319-50482-7

Brodtkorb TH, Earnshaw SR, Mauskopf J. Estimating treatment-related costs. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.71-90. doi: 10.1007/978-3-319-50482-7

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 21, 2017. Boston, MA. Previously presented at the ISPOR 20th Annual International Meeting.

Mauskopf J, Mullins CD, Earnshaw S. Budget impact analysis 1: a 6-step approach. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 21, 2017. Boston, MA. Previously presented at the ISPOR 18th Annual European Congress.

Jarmul JA, Pletcher MJ, Earnshaw S, Weinberger M, Jonas D, Avery C, Hassmiller Lich K, Wheeler S, Pignone M. Cardiovascular genetic risk testing for targeting statin therapy in the primary prevention of cardiovascular disease: a cost-effectiveness analysis. Presented at the 2017 (SGIM) Society of General Internal Medicine Annual Meeting; April 20, 2017. Washington, DC.

Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-effectiveness of maintaining daily intake of oat β-glucan for coronary heart disease primary prevention. Clin Ther. 2017 Apr;39(4):804-818.e. doi: 10.1016/j.clinthera.2017.02.012

Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017 Mar 24;2017(12):997-1008.

Wilson M, Wasserman M, Breton MC, McDade C, Earnshaw S, Farkouh R. Potential clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Canada. Poster presented at the 2016 Canadian Immunization Conference; December 6, 2016. Ottawa, Canada.

Mauskopf J, Earnshaw SR, Mullins CD, Brogan A. Building a budget impact model: budget impact analysis training. Presented at the 2016 ISPOR Training Courses; November 2016. Durham, NC.

Mauskopf J, Earnshaw S. A methodological review of US budget-impact models for new drugs. Pharmacoeconomics. 2016 Nov;34(11):1111-31. doi: 10.1007/s40273-016-0426-8

Earnshaw SR, Mullins CD, Brogan AJ. Budget impact analysis I: a 6-step approach. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 18th Annual European Congress.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 20th Annual International Meeting.

Wilson M, Lim J, Gandhi P, Wang C, Sander S, McDade C, Earnshaw S. Economic analysis of oral anticoagulants in the prevention of vascular events in Medicare patients with nonvalvular atrial fibrillation. Poster presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 25, 2016. Vancouver, Canada.

Demarteau N, Standaert B, Earnshaw S. Mathematical programming modeling to optimise allocation of healthcare interventions. In: Ethgen O, Staginnus U, editors. The future of health economics. New York: NY. Routledge; 2016.

Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.

Mauskopf JA, Mullins CD, Earnshaw SR. Budget impact analysis I: a 6-step approach. Presented at the 2016 ISPOR 21st Annual International Meeting; May 22, 2016. Washington, DC. Previously presented at the ISPOR 18th Annual European Congress.

Earnshaw SR, Brogan A, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 21st Annual International Meeting; May 22, 2016. Washington, DC. Previously presented at the ISPOR 20th Annual International Meeting.

Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.

Graham J, Xuan D, Luthra R, Borker R, Earnshaw SE, Lim J. Budget impact analysis of afatinib for the first-line treatment of metastatic non-small cell lung cancer patients with epidermal growth factor receptor exon 19 deletion mutations in a U.S. health plan. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S30.

Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273

Mauskopf JA, Mullins D, Earnshaw SR. Budget impact analysis I: a 6-step approach. Presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

Earnshaw SR, Kauf TL, McDade C, Potashman MH, Pauyo C, Reese ES, Senagore A. Economic impact of alvimopan considering varying definitions of postoperative ileus. J Am Coll Surg. 2015 Nov;221(5):941-50. doi: 10.1016/j.jamcollsurg.2015.08.004

Earnshaw S, Brogan A, Wolowacz S. Budget impact analysis II: applications & design issues. Presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. Previously presented at the ISPOR 20th Annual International Meeting.

Graham J, Luthra R, Earnshaw S, Borker R. Cost-effectiveness of afatinib vs. erlotinib in the 1st-line treatment of metastatic NSCLC patients with EGFR exon 19 deletion mutations. Poster presented at the 16th World Conference on Lung Cancer; September 6, 2015. Denver, CO.

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015 Jun 1;37(6):1317-28. doi: 10.1016/j.clinthera.2015.03.021

Mauskopf JA, Earnshaw SR, Mullins D. Introduction to budget impact analysis: a 6-step approach. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. Previously presented at the ISPOR 19th Annual International Meeting.

Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621

Earnshaw SR, Brogan AJ, Wolowacz SE. Budget impact analysis II: applications and design issues. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Qin L, Chen Y, Lesher B, Qifa L, Charbonneau C, Earnshaw SR, McDade CL, Mao N, Gao X. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected aspergillus invasive fungal infections in China. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A237.

Patel J, Coleman A, Wilson M, McDade C, Carr S, Earnshaw S. Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr 7; 21(4a):S55.

Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock S. Treatment interruption and regimen change in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. JHEOR. 2015 Apr;2(2):181-91.

Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock SJ. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Curr Med Res Opin. 2015 Feb;31(2):289-97.

Mauskopf JA, Earnshaw SR, Mullins CD. Introduction to budget impact analysis: a 6-step approach. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. Previously presented at the ISPOR 19th Annual International Meeting.

Mauskopf JA, Standaert B, Earnshaw SR, Connolly M. Changing perspectives, changing values: moving beyond cost-effectiveness analysis. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.

Earnshaw SR, Mullins CD, Brogan AJ, Wolowacz SE. Budget impact analysis: applications and design issues. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. Previously presented at the 2014 ISPOR 19th Annual International Meeting.

Hogue SL, Brogan AP, Earnshaw SR, Khan S, Nelsen S. Academy of Managed Care Pharmacy (AMCP) dossiers: use in health care decision making. Poster presented at the 2014 AMCP Nexus; October 8, 2014. Previously presented at the ISPOR 19th Annual International Conference.

Ward MA, Fang G, Richards K, Walko C, Earnshaw SR, Happe LE, Blalock SJ. Comparative outcomes of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Poster presented at the 2014 AMCP Nexus; October 2014.